162 Bronchial artery embolization (BAE) in adults with cystic fibrosis: a single-centre case series

Over the past last few decades, cystic fibrosis (CF) has changed from a disease of childhood into a disease of adults. When a chronic infection of the lungs occurs, eradication of the pathogens is almost impossible. In the Institute for Pulmonary Diseases of Vojvodina, we have started the treatment of adult patients with cystic fibrosis in the year of 2010. The aim of the study is to examine the patterns of antimicrobial susceptibility of the pathogens isolated from adult patients with cystic fibosis due to a rational use of antimicrobial therapy. The results are shown for the first six adult patients with cystic fibrosis treated in the Institute, 5 females and 1 male, at the average age of 24.8 years. The following microorganisms were isolated from sputum samples: Pseudomonas aeruginosa 15 (45.5%), Pseudomonas species 11 (33.3%), Escherichia coli 5 (15.2%), Klebsiella pneumoniae 1 (3%), Staphylococcus aureus 1 (3%). The isolated microorganisms showed high susceptibility rates to piperacillin–tazobactam (85.7%) meropenem (81.8%), imipenem (78.8%), cefepime (81.8%), ceftazidime (78.8%), ceftriaxone (72.2%). Susceptibility to ciprofloxacin was 68.7%, and to gentamicin 59.4%. Besides high susceptibility rates to carbapenems, similarly high susceptibility rates of the isolated microorganisms were registered to the third and fourth generation of cephalosporins. The goal of monitoring the resistance of pathogens isolated from the patients with cystic fibrosis and the rational use of antimicrobial therapy is to reduce the number of microorganisms and to maintain the patients’ pulmonary function and decrease an irreversible damage of the pulmonary parenchyma.